TRT (Trio-Tech International) Stock Analysis - News
Trio-Tech International (TRT) is a publicly traded Technology sector company. As of May 21, 2026, TRT trades at $13.24 with a market cap of $154.93M and a P/E ratio of 325.75. TRT moved -3.01% today. Year to date, TRT is +109.61%; over the trailing twelve months it is +438.27%. Its 52-week range spans $2.31 to $21.38. Rallies surfaces TRT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in TRT news today?
Hantavirus Surge Highlights Opportunity for TRT’s Broad‐Spectrum Antiviral Candidate: Health officials have reported rising hantavirus cases across the US Southwest, underscoring the absence of approved antiviral treatments. Investors are eyeing TRT’s broad‐spectrum polymerase inhibitor candidate, now in preclinical evaluation against hantaviruses and other emerging RNA viruses.
ADELMAN JASON T sold 9.36K (~$131.11K) on May 19, 2026.
ADELMAN JASON T sold 5.62K (~$78.47K) on May 19, 2026.
ADELMAN JASON T sold 10.00K (~$187.60K) on May 18, 2026.
TRT Analyst Consensus
TRT analyst coverage data. Average price target: $0.00.
Common questions about TRT
What changed in TRT news today?
Hantavirus Surge Highlights Opportunity for TRT’s Broad‐Spectrum Antiviral Candidate: Health officials have reported rising hantavirus cases across the US Southwest, underscoring the absence of approved antiviral treatments. Investors are eyeing TRT’s broad‐spectrum polymerase inhibitor candidate, now in preclinical evaluation against hantaviruses and other emerging RNA viruses.
Does Rallies summarize TRT news?
Yes. Rallies summarizes TRT news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is TRT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TRT. It does not provide personalized investment advice.
